Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -1578.79% is 111% below its 5-year average of -746.60%, near the high end of its 5-year range (-38229.49%–1867.51%).
80.09% above its 12-month average of -7928.92%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -16748.27%.
NET PROFIT MARGIN
-1578.79%
NET PROFIT MARGIN AVG TTM
-7928.92%
NET PROFIT MARGIN AVG 3Y
-3372.97%
NET PROFIT MARGIN AVG 5Y
-746.60%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+80.09%
CURRENT VS 3Y AVG
+53.19%
CURRENT VS 5Y AVG
-111.46%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-607126.92%
vs the sector median at left
Onconetix, Inc.
Market Cap
$2.37M
Net Profit Margin
-1578.79%
TTM Avg
-7928.92%
3Y Avg
-3372.97%
5Y Avg
-746.60%
Market Cap
$2.37M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.38M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.38M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.32M
Net Profit Margin
-201355.37%
TTM Avg
-74928.77%
3Y Avg
-55011.63%
5Y Avg
-36705.99%
Market Cap
$2.44M
Net Profit Margin
-131.76%
TTM Avg
-396.75%
3Y Avg
-403.38%
5Y Avg
-531.17%
Market Cap
$2.54M
Net Profit Margin
-257.33%
TTM Avg
-169.26%
3Y Avg
-42605.81%
5Y Avg
-28403.87%
Market Cap
$2.56M
Net Profit Margin
-123.38%
TTM Avg
-169.81%
3Y Avg
-184.41%
5Y Avg
-199.55%
Market Cap
$2.14M
Net Profit Margin
-122.42%
TTM Avg
-97.90%
3Y Avg
-110.76%
5Y Avg
-109.24%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Onconetix, Inc. (ONCO) | $2.37M | -1578.79% | -7928.92% | -3372.97% | -746.60% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | -201355.37% | -74928.77% | -55011.63% | -36705.99% |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | -131.76% | -396.75% | -403.38% | -531.17% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | -257.33% | -169.26% | -42605.81% | -28403.87% |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | -123.38% | -169.81% | -184.41% | -199.55% |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | -122.42% | -97.90% | -110.76% | -109.24% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | -862.34% | -747.16% | -4673.17% | -3945.34% |
Operating Margin
-778.2%
Net Profit Margin
-1578.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -16748.27% |
| 2026-03-31 | -19643.36% |
| 2025-12-31 | 1867.51% |
| 2025-09-30 | -2892.70% |
| 2025-06-30 | -2227.77% |
| 2025-03-31 | -8408.82% |
| 2024-12-31 | -4134.74% |
| 2024-09-30 | -940.72% |
| 2024-06-30 | -2029.76% |
| 2024-03-31 | -1587.39% |
| 2023-12-31 | -38229.49% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-03-31 | 0.00% |
